Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Evotec AG (EVO)
NASDAQ:EVO
Holding EVO?
Track your performance easily
EVO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.85 - $12.00
Previous Close$4.58
Volume152.82K
Average Volume (3M)128.12K
Market Cap
$1.56B
Enterprise Value$899.63M
Total Cash (Recent Filing)€604.11M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.52
Shares Outstanding354,371,472
10 Day Avg. Volume206,492
30 Day Avg. Volume128,116
Standard Deviation0.14
R-Squared0.24
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.22
Price to Sales (P/S)1.86
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.20Price Target Upside60.41% Upside
Rating ConsensusHold
Number of Analyst Covering4
Evotec AG News
PremiumCompany Announcements
Evotec Reports Strategic Growth Amidst Revenue Challenges
PremiumCompany Announcements
Evotec AG Strengthens Alliances Amidst Revenue ChallengesPremiumPre-Earnings
Is EVO a Buy, Before Earnings?
PremiumCompany Announcements
Evotec AG Posts Modest Revenue Growth Amidst Cost Challenges
Bulls Say, Bears Say
Bulls Say
Financial PerformancePriority reset on track for over €40M+ Adjusted EBITDA improvement by FY25 with a €10M positive impact expected in the second half.
Leadership And InnovationThe new CEO, Dr. Christian Wojczewski, announced accelerated transformation programs and rebuilt the core innovation strengths of the company.
Strategic PartnershipsEvotec recently expanded its BMY molecular glue collaboration and initiated a cell therapy collaboration with Novo Nordisk.
Bears Say
Financial PerformanceEvotec's recent results fell below expectations with sales significantly underperforming, highlighting ongoing financial challenges.
Market OutlookPersisting elongated deal cycles and weak early-stage R&D funding suggest a prolonged period of unstable results.
Operational ChallengesManagement's efforts to restructure expenses, including workforce and facility reductions, risk causing additional disruptions.
---
Ownership Overview
―
Insiders
0.08% Mutual Funds
0.05% Other Institutional Investors
99.87% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.85 and its highest was $12.00 in the past 12 months.
What is Evotec AG’s market cap?
Currently, no data Available
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Mar 27, 2025 which is in 140 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG does not currently pay dividends.
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,106,780 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
---
Evotec AG Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$6.20 (60.41% Upside)
$6.20 (60.41% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average 72%
Sector Average 72%
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-51.27%
12-Months-Change
Fundamentals
Return on Equity
-15.59%
Trailing 12-Months
Asset Growth
-14.67%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmes on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.
---
EVO Earnings Call
Q3 2024
0:00 / 0:00
---
EVO Stock 12 Month Forecast
Average Price Target
$6.20
▲(60.41% Upside)
Technical Analysis
Best Analysts Covering EVO
1 Year
1 Year Success Rate
2/8 ratings generated profit
1 Year Average Return
-18.00%
reiterated a buy rating 3 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of -18.00% per trade.
---